Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.




This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Oncology

Articles with lock require a GLG News subscription
Kenneth Algazy Posted May 19, 2008
The gods giveth and then takith away- Go figure.....
Analysis of: First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations | jco.ascopubs.org
Author: Kenneth Algazy, Clinical Professor of Medicine University of Pennsylvania School of Medicine - CC
Two papers, the one above, and http://jco.ascopubs.org/cgi/content/full/26/15/2450 reveal somewhat conflicting data on AstraZeneca's Iressa that was until now on the "back burner" due to Genentech's Tarceva, that had better response data than Iressa in separate trials On one hand the first paper points...
Donald Fleming Posted May 19, 2008
BRCA Mutations less risky than thought
Analysis of: Cancer-Gene Test Boosts Myriad's Sales | online.wsj.com
Author: Donald Fleming, Division Head of Hematology and Oncology Davis Health System, Inc.
New data indicates risk of invasive breast cancer in women with either BRCA mutation maybe less than previuosly thought This new information will adversely impact Myriad's business
Kenneth Algazy Posted May 19, 2008
Alimta (Lilly): YES!!!!
Analysis of: Lilly Drug Shown to Slow Lung Cancer | online.wsj.com
Author: Kenneth Algazy, Clinical Professor of Medicine University of Pennsylvania School of Medicine - CC
That Alimta can be effectively used after other chemotherapy in non small cell lung cancer (NSCLC) as a maintenance agent!
Ken Powell Posted May 15, 2008
Study of Breast Cancer Risk May Impact Myriad Genetics
Analysis of: Cancer-Gene Test Boosts Myriad's Sales | online.wsj.com
Author: Ken Powell, President Genesis Business Development
A new study published in the Journal of the American Medical Association estimated a lower risk of developing breast cancer by the age of 70 in women carrying mutations in one of two genes (BRAC1 and BRAC2).  This comes at the same time as Myriad Genetics (MYGN(NMS:MYGN)) is marketing their...
Posted May 14, 2008
Novelos Therapeutics announces positive results in ongoing phase 2 neoadjuvant breast cancer trial as Musc Hollings Cancer Center
Analysis of: Novelos Therapeutics announces positive results in ongoing phase 2 neoadjuvant breast cancer trial as Musc Hollings Cancer Center | www.pipelinereview.com
Author: GLG Member Program Contributor
The positive interim results released by Novelos Therapeutics about its chemoprotectant / chemopotentiator NOV-002 were not very meaty: Divining the true implications of pathologic CRs in neo-adjuvant breast cancer can be tricky.  Plus, this was a open label, phase II study, and the number of patients reported...
Kenneth Algazy Posted May 13, 2008
GSK: Gutsy but logical clinical trial of Tykerb v Herceptin (Genentech)
Analysis of: Glaxo Tests Tykerb vs Herceptin in Early Cancer | www.therapeuticsdaily.com
Author: Kenneth Algazy, Clinical Professor of Medicine University of Pennsylvania School of Medicine - CC
Glaxo is trying to move Tykerb ahead of Herceptin in a first line/neoajuvant/adjuvant setting in Her2Neu + Breast cancer.
Kenneth Algazy Posted May 12, 2008
ImClone: Does Morgan Stanley (MS) know something we don't??
Analysis of: US Drug Stocks Edge Higher, But ImClone Falls On Downgrade | news.ino.com
Author: Kenneth Algazy, Clinical Professor of Medicine University of Pennsylvania School of Medicine - CC
Erbitux was touted to have a positive study in Non Small Cell Lung Cancer (NSCLCA) but all they said was that is was a positive study. No further info at that time but an executive bought a block of stock a few days before the announcement which led to an inevitable rise in the stock price! Does this...
Posted May 12, 2008
Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market
Analysis of: Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market | www.pipelinereview.com
Author: GLG Member Program Contributor
Now that liquid Leukine (GM-CSF) has been withdrawn by Bayer, Amgen commands the North American G-CSF market with its Neupogen and Neulasta.  However, Indian manufacturer INTAS Biopharmaceuticals Ltd. (IBPL) has been treating patients with a biosimilar G-CSF called Neukine since 2004.  And...
Donald Fleming Posted May 9, 2008
ASA404 approach in treating lung cancer
Analysis of: ASA404 begins pivotal trial to explore new approach in treating lung cancer, the leading cause of cancer death | www.pipelinereview.com
Author: Donald Fleming, Division Head of Hematology and Oncology Davis Health System, Inc.
ASA404 begins pivotal trial to explore new approach in treating lung cancer ASA404 is a drug that helps chemo treat lung cancer yet eliminate exisiting blood vessels supplying the tumors
Posted May 7, 2008
Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients with Relapsed Solid Tumors
Analysis of: Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients with Relapsed Solid Tumors | www.pipelinereview.com
Author: GLG Member Program Contributor
The fact that they had a very small phase I studay of 14 patients only.  This concerns me a bit.  Usualy you enrol at least 30-40 patients in a phase I trial
Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Next41 to 50 of 680

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics